GlassScriptPhysician profile
Stephen Christopher Wheelis
NPI 1174010318
$8,605.87
in general payments reported to CMS, 2019-2025
18 companies · $773 in 2025
The $773 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $19.97 · 2022: $2,641 · 2023: $2,066 · 2024: $2,958 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,126 · Food and Beverage: $2,594 · Education: $68.49 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,125.85 |
| Food and Beverage | $2,594.41 |
| Education | $68.49 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $3,767.11 | 2022-2025 | Phasix Mesh |
| Becton, Dickinson and Company | $2,410.41 | 2023-2024 | Phasix Mesh |
| Intuitive Surgical, INC. | $1,426.62 | 2022-2024 | |
| Stryker Corporation | $174.55 | 2023 | Spy-Phi System |
| Conmed Corporation | $147.78 | 2019 | |
| Kerecis Limited | $138.50 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| La Jolla Pharmaceutical Company | $94.72 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $89.41 | 2025 | Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $77.26 | 2024-2025 | Keytruda, Lenvima |
| Solventum Corporation | $55.51 | 2024 | V.A.C. Veraflo, Prevena |
| Stemline Therapeutics INC. | $48.73 | 2024-2025 | Orserdu |
| Vertex Pharmaceuticals Incorporated | $35.50 | 2024-2025 | |
| Integra Lifesciences Corporation | $34.90 | 2023 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Bayer Healthcare Pharmaceuticals INC. | $26.03 | 2025 | |
| Medtronic, INC. | $24.24 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $19.97 | 2020 | |
| Ethicon US, LLC | $17.78 | 2025 | Evarrest |
| Genentech USA, INC. | $16.85 | 2025 | Polivy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Wheelis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.